USSubmitted label - approval not established

MELODY CLOVERSTRIP (CANNABIDIOL HEMP OIL) STRIP

This is a locally preserved regulatory record. Source labeling does not by itself prove efficacy for a condition.

Submitted product label. A product label is preserved locally, but approval or current marketing status is not established.

Product data

Locally preserved regulatory fields

Active ingredients: cannabidiol
Route: Not reported
Dosage form: Not reported
Marketing holder: ADVANCED MEN'S INSTITUTE
Catalog status: Submitted label - approval not established
Source-reported status: Not reported

Medicine name group

2 preserved variants

Records share the same exact normalized name. Different identifiers, strengths, countries, presentations and statuses remain separate.

Submitted label - approval not establishedUSCurrent record

MELODY CLOVERSTRIP (CANNABIDIOL HEMP OIL) STRIP

Strength not reported

Route and form not reported

2 identifiers · DailyMed structured labels

Submitted label - approval not establishedUS

MELODY CLOVERSTRIP (CANNABIDIOL HEMP OIL) STRIP

Strength not reported

Route and form not reported

2 identifiers · DailyMed structured labels

Linked local records

Related local records

Substance links use source-reported active ingredients. Condition links come from registered study context and are not efficacy claims.

Cannabinoids and active compounds

cannabidiol

Condition reports

epilepsy Chronic Pain Multiple Sclerosis Parkinson Disease Alzheimer Disease Anxiety Disorders Cancer Pain Stress Disorders, Post-Traumatic Opioid-Related Disorders Alcoholism Bipolar Disorder

Regulatory record

Approval, patents and exclusivity

Patent and exclusivity fields are preserved from the regulator. They are not a legal opinion and are separate from clinical development.

0approval records

0source-reported patents

0exclusivity records

Clinical development

Related registered studies

Phases and statuses are source-reported study stages matched by governed token phrases. They do not prove medicine identity, approval or efficacy.

371candidate study links

PHASE1 · PHASE2RECRUITING

Pathophysiological Mechanisms of Cannabidiol in Stress Regulation

DRUG · Cannabidiol

Early Life Adversity · Trauma · Stress

PHASE3RECRUITING

CardiolRxTM in Recurrent Pericarditis (MAVERIC Phase 3) A Randomized, Double-blind, Placebo-controlled Trial

DRUG · CardiolRx

Recurrent Pericarditis

PHASE2RECRUITING

The Differential Effects of THC vs. CBD on Cognition in Persons With MS

DRUG · CBD

Multiple Sclerosis

PHASE2RECRUITING

Cannabinoid Interactions With Central and Peripheral Pain Mechanisms in Osteoarthritis of the Knee

DRUG · Cannabidiol (CBD)

Osteoarthritis, Knee · Osteoarthritis of the Knee

PHASE2COMPLETED

A Phase 2A Study to Investigate the Safety and Preliminary Analgesic Efficacy of Oral Trichomylin® in Male and Female Participants 18 Years of Age and Above With Advanced Cancer and Moderate to Severe Cancer-Related Pain

DRUG · Trichomylin® capsule (5 mg delta-9-tetrahydrocannabinol: 5 mg cannabidiol: 5 mg cannabichromene)

Cancer Pain

Source-reported use

Indications in regulatory records

No indication text was reported by the connected sources.

Medicine identity matching